Timing of teriparatide for postmenopausal osteoporosis
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This trial is studying whether the time of day you receive teriparatide (a bone-building drug) affects its effectiveness for postmenopausal women with osteoporosis. You may be eligible if you have very low bone density, are between 60 and 70, and are at least 5 years past your last period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 60 and 70 years old.
- You are naturally postmenopausal and it has been at least 5 years since your last period.
- You have very low bone density, measured as a T-score of -3.0 or lower in your lower spine or hip.
- Your vitamin D level is at least 20 ng/mL (can be corrected with supplements before testing).
- Your blood levels of PTH and calcium are in the normal range.
- You have not used certain medications (like bisphosphonates, teriparatide, or denosumab) within the past 6 months to 2 years, depending on the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two bone-building drugs (romosozumab and teriparatide) in postmenopausal women with osteoporosis who are at high risk for fractures. The goal is to see if the combination strengthens bones faster and better than either drug alone.
This study is a follow-up for people who completed a previous precision medicine trial for osteoporosis. It will monitor your bone health to see how well the treatment is working over time.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This trial tests whether a specific exercise program (circuit training) can improve bone density in women after menopause who have low bone mass. It may help strengthen bones and reduce fracture risk.
This study tests a new form of calcium (amorphous calcium carbonate) to see if it can improve bone density in postmenopausal women with osteoporosis. It may offer an alternative for women who cannot or choose not to take other osteoporosis medications.
This trial tests teriparatide (a hormone-like bone medicine) to improve bone health in people with advanced chronic kidney disease who are at risk for weak, low-turnover bone. It may help by changing how quickly your bones break down and rebuild.
Hear when a new Circadian Rhythm Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.